13^th World Biomarkers Congress

Xuemei is currently a Senior Principal Scientist in the Translational Molecular Biomarkers Department at Merck & Co., Inc. in Rahway, NJ. She received her Ph.D. in Chemistry from Columbia University and performed her postdoctoral research at Cold Spring Harbor Laboratory. Afterwards, Xuemei joined the Proteomics Department in Molecular Profiling at Merck in 2004. She led the biochemistry group focusing on sample preparation for LC-MS based proteomics profiling for biomarker discovery and new target identification. In 2012, Xuemei transitioned to clinical biomarker development. Currently, she leads the immunoassay group focusing on clinical biomarker assay development, validation, and implementation to support drug development clinical studies across all disease areas at Merck.

Immunoassay group focusing on clinical biomarker assay development, validation, and implementation to support drug development clinical studies across all disease areas at Merck.

Biography Sergey Suchkov graduated from Astrakhan State Medical University and awarded with MD, then in 1985 maintained his PhD at the I.M. Sechenov Moscow Medical Academy and in 2001, maintained his Doctorship Degree at the Nat Inst of Immunology, Russia. From 1987 through 1989, he was a senior Researcher, Koltzov Inst of Developmental Biology. From 1989 through 1995, he was a Head of the Lab of Clinical Immunology, Helmholtz Eye Research Institute in Moscow. From 1995 through 2004, a Chair of the Dept for Clinical Immunology, Moscow Clinical Research Institute (MONIKI. Dr Suchkov has been trained at: NIH; Wills Eye Hospital, PA, USA; Univ of Florida in Gainesville; UCSF, S-F, CA, USA; Johns Hopkins University, Baltimore, MD, USA. He was an Exe Secretary-in-Chief of the Editorial Board, Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK. At present, Dr Sergey Suchkov is a Chair, Dept for Personalized and Translational Medicine, I.M.Sechenov First Moscow State Medical University. He is a member of the: New York Academy of Sciences, USA; American Chemical Society (ACS), USA; American Heart Association (AHA), USA; EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU; ARVO (American Association for Research in Vision and Ophthalmology); ISER (International Society for Eye Research); PMC (Personalized Medicine Coalition), Washington, USA.

Personalized and Translational Medicine, Clinical Immunology, Preventive and Personalized Medicine

Dr. Luo been studying molecular pathology related to human malignancies in the last 27 years. Currently, he is a Professor of Pathology and Director of High Throughput Genome Center at University of Pittsburgh. In the last 15 years, Dr. Luo has been largely focusing on genetic and molecular mechanism of human prostate and hepatocellular carcinomas. In this period, his group has identified and characterized several genes that are related to prostate cancer and hepatocellular carcinoma, including SAPC, myopodin, CSR1, GPx3, ITGA7, MCM7, MT1h and GPC3. He has characterized several signaling pathways that play critical role in prostate cancer development, including Myopodin-ILK-MCM7 inhibitory signaling, myopodin-zyxin motility inhibition pathway, CSR1-CPSF3 and CSR1-XIAP apoptotic pathways, MT1h-EHMT1 egigenomic signaling, ITGA7-HtrA2 tumor suppression pathway, GPx3-PIG3 cell death pathway, and AR-MCM7 oncogenic pathway. He proposed prostate cancer field effect in 2002. He is one of the pioneers in utilizing high throughput gene expression and genome analyses to analyze field effects in prostate cancer and liver cancer. He is also the first in using methylation array and whole genome methylation sequencing to analyze prostate cancer. Recently, Dr. Luo’s group found that patterns of copy number variants of certain specific genome loci are predictive of prostate cancer clinical outcomes, regardless tissue origin. His discovery of several novel fusion transcripts and their association with aggressive prostate cancer has brought significant new insight into the field of prostate cancer research. Overall, these discoveries advance our understanding on how cancer develops and behaves, and lay down the foundation for better future diagnosis and treatment of human malignancies.

Hepatocellular Carcinomas , Prostate Cancer , Genome Analysis

Kaushala Prasad Mishra has earned B.Sc and M.Sc. degrees from Allahabad University and Ph.D. from Gujarat University. His areas of Specialization: Life Sciences, Radiation Biology, Biotechnology, Biophysics and chemistry. He has been Research Guide for Ph.D. students in many Universities of India; Successfully guided 41 Ph.D. students and presently guiding 08 students. He has published more than 280 research papers and proceeding papers in National and International Journals. He has delivered more than 300 invited talks in Symposia and Conferences. He is currently the Vice Chancellor of Nehru Gram Bharati University, Allahabad, India. He also served as Head, Radiation Biology and Health Science Division and Senior Scientific Officer of Bhabha Atomic Research Center, Department of Atomic Energy, and Government of India, Chairman, Standing Selection Committee, Member, Trombay Scientific Council, BARC, Member, Health, Safety & Biomedical Group Board, Member, Committee of Atomic Energy Commission on Health and Environment Aspects of Uranium Mining at Jaduguda, Member, Core Expert Group on Chemical Disaster and Nuclear Disaster Management of National Disaster Management Authotrity of India (NDMA). He served as Chancellor's Nominee in Selection Committees of Padmashri Dr. D.Y. Patil Deemed University; Mumbai and West Bengal University of Technology, Kolkata and served as Expert on Selection Committees of IITs and several Universities in India.

Radiation Research, Biomarkers, Biophysics, Biotechnology

Youhe Gao is a Professor in Beijing Normal University. He received his MD from Peking Union Medical College and his from PhD from University of Connecticut and Postdoctoral training from Beth Israel Deaconess Medical Center, Harvard Medical School. He was the Professor of Department of Pathophysiology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences/ Peking Union Medical College from 2001-2014. His research interests include biomarker discovery in urine, urine biobanking, protein interaction methods and related bioinformatics

Pathophysiology, Biomarkers, Bioinformatics, Biobanking

Professional experience in oncology circles, supported by multiple collaborations with major hospitals, allowed LOUIS CAZE to benefit from a reference fame as an Expert Support Care. First, Specialist lymphatic, muscular and circulatory LOUIS CAZE makes the total body approach his chosen field. It captures the benefits of physical-mental balance in the treatment of chronic diseases, and specializes in supportive care dedicated to cancer diseases. His collaboration with renowned organizations such as the Institute Gustave Roussy, was punctuated with exceptional professional and human experience. LOUIS CAZE is involved in implementing a comprehensive approach to cancer patient, in a real project of care that optimizes patient's quality of life, ensuring the different key aspects of health: the well physical and psychological, but also the entire social and family interactions. After these experiences, LOUIS CAZE work for the development of Support Care, including the management of pain and psychology.

LOUIS CAZE is involved in implementing a comprehensive approach to cancer patient, in a real project of care that optimizes patient's quality of life, ensuring the different key aspects of health: the well physical and psychological, but also the entire social and family interactions. After these experiences, LOUIS CAZE work for the development of Support Care, including the management of pain and psychology.

Xuemei is currently a Senior Principal Scientist in the Translational Molecular Biomarkers Department at Merck & Co., Inc. in Rahway, NJ. She received her Ph.D. in Chemistry from Columbia University and performed her postdoctoral research at Cold Spring Harbor Laboratory. Afterwards, Xuemei joined the Proteomics Department in Molecular Profiling at Merck in 2004. She led the biochemistry group focusing on sample preparation for LC-MS based proteomics profiling for biomarker discovery and new target identification. In 2012, Xuemei transitioned to clinical biomarker development. Currently, she leads the immunoassay group focusing on clinical biomarker assay development, validation, and implementation to support drug development clinical studies across all disease areas at Merck.

, she leads the immunoassay group focusing on clinical biomarker assay development, validation, and implementation to support drug development clinical studies across all disease areas at Merck.

Youhe Gao Professor Beijing Normal University. He received his MD from Peking Union Medical College, his Ph.D from University of Connecticut and postdoctoral training from Beth Israel Deaconess Medical Center, Harvard Medical School. He was the professor of Department of Pathophysiology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences/ Peking Union Medical College from 2001-2014. His research interests include biomarker discovery in urine, urine biobanking, protein interaction methods and related bioinformatics.

His research interests include biomarker discovery in urine, urine biobanking, protein interaction methods and related bioinformatics.

Dr A-Lien Lu-Chang completed her PhD from University of North Carolina at Chepel Hill and postdoctoral studies from Duke University School of Medicine with Dr. Paul Modrich (Nobel laureate in Chemistry in 2015). She is the Professor of Biochemistry and Molecular Biology at University of Maryland Medical School and a member of University of Maryland Greenebaum Comprehensive Cancer Center. She has published more than 63 peer-reviewed papers in reputed journals, holds a potent, and has been serving as an editorial board members of four journals.

My laboratory is studying the interplays among DNA repair, DNA replication, cell cycle checkpoint, transcription, and chromatin remodeling. We investigate the impact of their coordination on telomere integrity and carcinogensis. Our work highlights potential targets that can be exploited clinically for cancer therapies.

Sergey Suchkov graduated from Astrakhan State Medical University and was awarded with MD. In 1985, Suchkov obtained his Ph.D. He is the PhD student of the I.M. Sechenov Moscow Medical Academy and Institute of Medical Enzymology, USSR Academy of Medical Sciences, Moscow, Russia. In 2001, Suchkov finished the PostDoc Research Fellowship Program and maintained his Doctor Degree at the National Institute of Immunology, Russia. From 1987 through 1989, Dr. Suchkov was a senior Researcher, Lab of Developmental Immunology, Koltzov Institute of Developmental Biology, USSR Academy of Sciences to deal to developmental immunology. From 1989 through 1995, Dr. Suchkov was being a Head of the Lab of Clinical Immunology and Immunobiotechnology, Helmholtz Eye Research Institute in Moscow. From 1995 through 2004, Dr. Suchkov was being a Chairman of the Department for Clinical Immunology, Moscow Clinical Research Institute (MONIKI) and the Immunologist-in-Chief of the Moscow Regional Ministry of Health. At present, Dr Sergey Suchkov, MD, PhD, is Professor in Immunology, Department of Pathology, School for Pharmacy, I.M. Sechenov First Moscow State Medical University, Dean of the Department (Faculty) of The PPPM Development, and the First Vice-President of the University of World Business, Politics and Law and Secretary General, United Cultural Convention (UCC), Cambridge, UK.

Enzymology, biomarkers, cardiology, Immunology.

Dr. Qing Kay Li is an associate professor of pathology at the Johns Hopkins University School of Medicine. She has the American Board of Pathology certification in anatomic and clinical pathology, and subspecialty certification in cytopathology. Her areas of clinical expertise include surgical pathology and cytopathology. Dr. Li is also a faculty member and co-PI at the Johns Hopkins Biomarker Discovery Center.

Her research interests are focusing on the application of advanced cellular and molecular techniques to the field of cytopathology and cancer biology, particularly in the field of early detection of lung and prostate cancer.

Dr. Hoque is an Associate Professor of Otolaryngology-Head & Neck Surgery, Urology and Oncology at Johns Hopkins University School of Medicine. Dr. Hoque completed dental and oral surgery training at the Dhaka Dental College, Dhaka University, Bangladesh. He then moved to Japan for the completion of Ph.D degree, where he also completed Advanced Clinical Training in Oral and Maxillofacial Surgery and Oncology. After training in Japan, he worked in the Head and Neck Cancer Research Division as a Postdoctoral Fellow under the mentorship of Dr. David Sidransky. He joined as a faculty member in 2006 in the Department of Otolaryngology-Head and Neck Surgery. His research interests includes: a) To understand molecular biologic basis of head and neck, lung and genitourinary cancer b) To develop and validate genetic and epigenetic approach for early cancer diagnosis, cancer risk assessment and cancer prognosis and c) To identify molecular alterations due to environmental exposures such as active smoking, passive smoking and arsenic.

Develop and validate genetic and epigenetic approach for early cancer diagnosis, cancer risk assessment and cancer prognosis; Molecular biologic basis of head and neck, lung and genitourinary cancer.

B.Sc and M.Sc. degrees from Allahabad University and Ph.D. from Gujarat University. Areas of Specialization: Life Sciences, Radiation Biology, Biotechnology, Biophysics and chemistry. Research Guide for Ph.D. students in many Universities of India. Successfully guided 41 Ph.D. students. Presently guiding 08 students. Published more than 280 research papers and proceeding papers in National and International Journals. Delivered more than 300 invited talks in Symposia and Conferences. Currently the Vice Chancellor of Nehru Gram Bharati University, Allahabad, India. Served as Head, Radiation Biology and Health Science Division and Senior Scientific Officer of Bhabha Atomic Research Center, Department of Atomic Energy, and Government of India. Chairman, Standing Selection Committee, Member, Trombay Scientific Council, BARC, Member, Health, Safety & Biomedical Group Board, Member, Committee of Atomic Energy Commission on Health and Environment Aspects of Uranium Mining at Jaduguda, Member, Core Expert Group on Chemical Disaster and Nuclear Disaster Management of National Disaster Management Authotrity of India (NDMA). Served as Chancellor's Nominee in Selection Committees of Padmashri Dr. D.Y. Patil Deemed University; Mumbai and West Bengal University of Technology, Kolkata and served as Expert on Selection Committees of IITs and several Universities in India.B.Sc and M.Sc. degrees from Allahabad University and Ph.D. from Gujarat University. Areas of Specialization: Life Sciences, Radiation Biology, Biotechnology, Biophysics and chemistry. Research Guide for Ph.D. students in many Universities of India. Successfully guided 41 Ph.D. students. Presently guiding 08 students. Published more than 280 research papers and proceeding papers in National and International Journals. Delivered more than 300 invited talks in Symposia and Conferences. Currently the Vice Chancellor of Nehru Gram Bharati University, Allahabad, India. Served as Head, Radiation Biology and Health Science Division and Senior Scientific Officer of Bhabha Atomic Research Center, Department of Atomic Energy, and Government of India. Chairman, Standing Selection Committee, Member, Trombay Scientific Council, BARC, Member, Health, Safety & Biomedical Group Board, Member, Committee of Atomic Energy Commission on Health and Environment Aspects of Uranium Mining at Jaduguda, Member, Core Expert Group on Chemical Disaster and Nuclear Disaster Management of National Disaster Management Authotrity of India (NDMA). Served as Chancellor's Nominee in Selection Committees of Padmashri Dr. D.Y. Patil Deemed University; Mumbai and West Bengal University of Technology, Kolkata and served as Expert on Selection Committees of IITs and several Universities in India.

Radiation Research, Biomarkers, Biophysics, Biotechnology

Dr. Suzuki worked in Research and Development Center, Hitachi Medical Co, Japan, from 1993 to 1997. From 1997 to 2001, he worked in Faculty of Information Science and Technology, Aichi Prefectural University, Japan, as a faculty member. In 2001, he joined Department of Radiology, University of Chicago, as Research Associate. He was promoted to Assistant Professor of Radiology, Graduate Program in Medical Physics, and Cancer Research Center in 2006. Since 2014, he has been Associate Professor in Medical Imaging Research Center and Department of Electric and Computer Engineering, Illinois Institute of Technology.

His research interests include computational intelligence and machine learning in medical imaging, computer-aided detection and diagnosis, and medical image processing and analysis. He published more than 230 papers (including 95 peer-reviewed journal papers) and 75 refereed abstracts.

Zeliha Selamoglu trained at the Department of Biology, Faculty of Arts and Science, Inonu University, Malatya, Turkey (Ph.D, 2005). She is at the Department of Biotechnology, Faculty of Arts and Science, Omer Halisdemir University, Nigde, Turkey at the now (Full. Prof., 2015). Her research interests include tyrosine tydroxylase activity, oxidative stress, antioxidants, selenium, bee products such as propolis and also natural products. Her current research concerns the antioxidant activity, in vivo oxidative stress by environmental chemicals and health risk assessment of environmental chemicals. The studing of heavy metals which environmental contaminants, toxic agents and trace metals which have some metabolic and environmental effects are important try fields. She has researched antihypertensive effects of organoselenium, bee products such as CAPE, pollen and propolis which played an important role in supression of oxidative stress, too. She has also researched biological activities of natural protective agents which is very important at detoxification of toxic chemicals. Besides, that the investigation of natural antioxidants which has metabolic significance and effects againts oxidative stress and hypertension in vivo. In addition to, synthetic antioxidants has been included her interested area. She has got two membership. These name are “Society for Experimental Biology and Medicine” and “European association for cancer research”. She has got reviewership some journals. Some of these: Antioxidants & Redox Signaling, Ecotoxicology and Environmental Safety, Iranian Journal of Fisheries Science, Fish Physiology and Biochemistry, Fresenius Environmental Bulletin, Biological Trace Element Research, Journal of Food Science, International Journal of Environmental Engineering Science, International Journal of Medicine and Medical Sciences, Experimental and Molecular Pathology, European Journal of Medicinal Chemistry, Current Drug Delivery, Asian Journal of Biochemistry, International Journal of Biological Chemistry, Journal of Pharmacology and Toxicology.

Her current research concerns the antioxidant activity, in vivo oxidative stress by environmental chemicals and health risk assessment of environmental chemicals. The studing of heavy metals which environmental contaminants, toxic agents and trace metals which have some metabolic and environmental effects are important try fields.

Zhigang Kang has completed his PhD from University of Helsinki, Finland and Post-doctoral studies from NIMH, NIH. He is a Research Scientist in Molecular Target Core, Genetics Branch, Center for Cancer Research, National Cancer Institute and an employee of Basic Science Program, Leidos Biomedical Research, Inc., Frederick. He has been working in the field of cancer biomarkers for the past 7 years. His research interests focus on the detection of invasive tumor biomarkers include circulating tumor cell (CTC), cell free circulating tumor DNA and clinical relevance protein markers from peripheral blood of patients with various types of tumors.

His research interests focus on the detection of invasive tumor biomarkers include circulating tumor cell (CTC), cell free circulating tumor DNA and clinical relevance protein markers from peripheral blood of patients with various types of tumors.

Zhigang Kang has completed his PhD from University of Helsinki, Finland and Post-doctoral studies from NIMH, NIH. He is a Research Scientist in Molecular Target Core, Genetics Branch, Center for Cancer Research, National Cancer Institute and an employee of Basic Science Program, Leidos Biomedical Research, Inc., Frederick. He has been working in the field of cancer biomarkers for the past 7 years. His research interests focus on the detection of invasive tumor biomarkers include circulating tumor cell (CTC), cell free circulating tumor DNA and clinical relevance protein markers from peripheral blood of patients with various types of tumors.

His research interests focus on the detection of invasive tumor biomarkers include circulating tumor cell (CTC), cell free circulating tumor DNA and clinical relevance protein markers from peripheral blood of patients with various types of tumors.

Hem D. Shukla is Research Scientist in Department of Pharmaceutical Sciences at University of Maryland and adjunct Professor of Genomics in Notre Dame of Maryland University. He has also worked as Research Faculty in Department of Biology at Johns Hopkins University. Dr. Shukla has worked on proteomic analysis of oxidative stress response in BxPC-3 pancreatic cell lines and identification of biomarkers for early detection of pancreatic cancer. He has worked on “The Nrf2 mediated antioxidant defense against oxidative stress in pancreatic cancer cell lines and targets for therapeutic intervention”. He has shown elevated level of Nrf2 transcriptional factor in pancreatic cancer cell lines under oxidative stress which is phosphorylated by protein kinase C and affects phosphatidylinositol 3-kinase and MAP kinase pathways. After phosphorylation, Nrf2 translocates to the nucleus, binds AREs and transactivates detoxifying enzymes and antioxidant enzymes, such as glutathione S-transferase, and superoxide dismutase. The IPA analysis has suggested a potential role of Nrf2 under oxidative stress conditions.

Proteomic analysis of oxidative stress response in BxPC-3 pancreatic cell lines Identification of biomarkers for pancreatic cancer Nrf2 mediated antioxidant defense against oxidative stress in pancreatic cancer cell lines.

David I Smith completed his Ph.D. at the age of 23 years from the University of Wisconsin in Madison and then did post-doctoral studies at the University of California in Irvine. Since 1996 he has been a Professor at the Mayo Clinic in the Department of Laboratory Medicine and Pathology. He is also the Chairman of the Technology Assessment Group for the Center for Individualized Medicine at the Mayo Clinic. His laboratory studies the common fragile sites and the role that these regions of instability play in the development of cancer. His group also studies the different ways that HPV can contribute to the development of different cancers. He has published over 200 papers in reputed journals and serves on the Editorial Board of a number of journals.

His group also studies the different ways that HPV can contribute to the development of different cancers. He has published over 200 papers in reputed journals and serves on the Editorial Board of a number of journals.

Dimitrios H. Roukos is currently working as Founding Director, Centre for Biosystems & Synthetic Genomic Network Medicine - CBS. GenNetMed Ioannina University- Ioannina, Greece. He is also Leader at Translational Research, European Network of Excellence (EUNE) for Gastric Cancer (since 2006) and affiliated to Department of Surgery, Ioannina University Hospital , Ioannina , Greece (since 1990). Dr. D. Roukos has graduated from Athens University School of Medicine, Greece. He underwent specialist training in surgery at the J.W.Goethe-University Hospital in Frankfurt a.M., Germany where received his Doctorate (Dr.med). He moved back to Greece and since 1990 works at the Ioannina University School of Medicine.

Genetics, Pathology, Biomarkers, Systems biology & and cancer networks

Shivendra V. Singh earned his M.Sc. and Ph.D. degrees in Biochemistry from the Banaras Hindu University (India). In 1983, Dr. Singh came to the United States to pursue post-doctoral training at the University of Texas Medical Branch, Galveston, TX and studied glutathione-linked detoxification mechanisms. In 1988, Dr. Singh was appointed to the faculty of the University of Miami, School of Medicine as an Assistant Professor in the Department of Medical Oncology. The Mercy Hospital of Pittsburgh recruited Dr. Singh in 1992 to head its Cancer Research Laboratory and direct basic cancer research program. Dr. Singh joined the University of Pittsburgh in 2000 as a Tenured Professor of Pharmacology & Chemical Biology and member of University of Pittsburgh Cancer Institute (UPCI). Dr. Singh holds a secondary appointment in the Department of Urology in School of Medicine, and is the Associate Director for Basic Research at the UPCI. Dr. Singh was honored with UPMC Endowed Chair Cancer Prevention Research in 2014. Dr. Singh is a co-author of over 240 research articles in peer-reviewed journals and 22 review articles/book chapters. Dr. Singh serves on Editorial Boards of various scientific journals, including Cancer Prevention Research, Molecular Cancer Therapeutics, Clinical Cancer Research, Molecular Pharmacology, Molecular Carcinogenesis, Carcinogenesis, and Pharmaceutical Research to name a few. Dr. Singh has served on various grant review panels.

Carcinogenesis, Cancer Therapeutics, Biomarkers

Dr Scherer obtained his PhD at the Max-Planck-Institute for Immunobiology in Germany. After a postdoctoral position at the UT Southwestern Medical Center in Dallas, USA, until 1999, he has been working on biomarker research and development projects in various positions, in the laboratory, as bioinformatician, and as project manager. Andreas worked for Novartis in Basel, CH, from 2000 until 2007, then as consultant and bioinformatician in his own company in Finland, and as Manager of the Bioinformatics Team at the Australian Genome Research Facility (AGRF) in Melbourne, AU. He is inventor and co-inventor of several biomarker-related gene patents, published a book on microarray data quality, and is involved in international research projects and consortia, such as the US FDA-guided SEQC. Besides his work in his consultancy company “Spheromics”, Andreas is Biomarker Project Director at the Institute for Molecular Medicine Finland (FIMM) at the University of Helsinki, Finland, and has a role as National Coordinator in Finland of the European Research Infrastructure for Translational Medicine, EATRIS, for which he also acts as Co-chair of the Biomarker technology Platform.

Biomarkers, Translational Medicine

Dimitrios H. Roukos is currently working as Founding Director, Centre for Biosystems & Synthetic Genomic Network Medicine - CBS. GenNetMed Ioannina University- Ioannina, Greece. He is also Leader at Translational Research, European Network of Excellence (EUNE) for Gastric Cancer (since 2006) and affiliated to Department of Surgery, Ioannina University Hospital , Ioannina , Greece (since 1990). Dr. D. Roukos has graduated from Athens University School of Medicine, Greece. He underwent specialist training in surgery at the J.W.Goethe-University Hospital in Frankfurt a.M., Germany where received his Doctorate (Dr.med). He moved back to Greece and since 1990 works at the Ioannina University School of Medicine.

Genetics, Pathology, Biomarkers, Systems biology & and cancer networks

Kaushala Prasad Mishra has earned B.Sc and M.Sc. degrees from Allahabad University and Ph.D. from Gujarat University. His areas of Specialization: Life Sciences, Radiation Biology, Biotechnology, Biophysics and chemistry. He has been Research Guide for Ph.D. students in many Universities of India; Successfully guided 41 Ph.D. students and presently guiding 08 students. He has published more than 280 research papers and proceeding papers in National and International Journals. He has delivered more than 300 invited talks in Symposia and Conferences. He is currently the Vice Chancellor of Nehru Gram Bharati University, Allahabad, India. He also served as Head, Radiation Biology and Health Science Division and Senior Scientific Officer of Bhabha Atomic Research Center, Department of Atomic Energy, and Government of India, Chairman, Standing Selection Committee, Member, Trombay Scientific Council, BARC, Member, Health, Safety & Biomedical Group Board, Member, Committee of Atomic Energy Commission on Health and Environment Aspects of Uranium Mining at Jaduguda, Member, Core Expert Group on Chemical Disaster and Nuclear Disaster Management of National Disaster Management Authotrity of India (NDMA). He served as Chancellor's Nominee in Selection Committees of Padmashri Dr. D.Y. Patil Deemed University; Mumbai and West Bengal University of Technology, Kolkata and served as Expert on Selection Committees of IITs and several Universities in India.

Radiation Research, Biomarkers, Biophysics, Biotechnology

Dr. (Prof.) Raisuddin is an academician, academic administrator and active researcher with a track record of over 25 years. He did his doctoral thesis (Ph.D.) work at the Indian Institute of Toxicology Research, IITR (a CSIR national laboratory), Lucknow. Initially, he worked as Scientist at IITR, Lucknow and Bose Institute, Kolkata. In 1994, he joined Jamia Hamdard (Hamdard University), New Delhi as a faculty in the Department of Medical Elementology & Toxicology. He was selected as Commonwealth Fellow in 2002 and worked for about a year at the University of Plymouth, UK as Visiting Scientist in 2003. In 2004, he visited Czech Republic under India National Science Academy (INSA) programme and spent three months as Visiting Scientist at RECETOX (an EU Centre of Excellence), Brno. For two years (2006-08) he was at Hanyang University (among top 5 Korean Universities), Seoul, South Korea as Professor. He has been the Head of the Department of Medical Elementology and Toxicology for three years (March 2012 – May 2015) and is currently Head of the Centre for Translational & Clinical Research. Dr. Raisuddin has been appointed as a member of editorial board of over a dozen international journals.

Biomarkers, Cancer markers, Molecular Biomarkers

Sergey Suchkov graduated from Astrakhan State Medical University and was awarded with MD. In 1985, Suchkov obtained his Ph.D. He is the PhD student of the I.M. Sechenov Moscow Medical Academy and Institute of Medical Enzymology, USSR Academy of Medical Sciences, Moscow, Russia. In 2001, Suchkov finished the PostDoc Research Fellowship Program and maintained his Doctor Degree at the National Institute of Immunology, Russia. From 1987 through 1989, Dr. Suchkov was a senior Researcher, Lab of Developmental Immunology, Koltzov Institute of Developmental Biology, USSR Academy of Sciences to deal to developmental immunology. From 1989 through 1995, Dr. Suchkov was being a Head of the Lab of Clinical Immunology and Immunobiotechnology, Helmholtz Eye Research Institute in Moscow. From 1995 through 2004, Dr. Suchkov was being a Chairman of the Department for Clinical Immunology, Moscow Clinical Research Institute (MONIKI) and the Immunologist-in-Chief of the Moscow Regional Ministry of Health. At present, Dr Sergey Suchkov, MD, PhD, is Professor in Immunology, Department of Pathology, School for Pharmacy, I.M. Sechenov First Moscow State Medical University, Dean of the Department (Faculty) of The PPPM Development, and the First Vice-President of the University of World Business, Politics and Law and Secretary General, United Cultural Convention (UCC), Cambridge, UK.

Enzymology, biomarkers, cardiology, Immunology.

Youhe Gao Professor Beijing Normal University. He received his MD from Peking Union Medical College, his Ph.D from University of Connecticut and postdoctoral training from Beth Israel Deaconess Medical Center Harvard Medical School. He was the professor of Department of Pathophysiology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences/ Peking Union Medical College from 2001-2014. His research interests include biomarker discovery in urine proteome, protein interaction and related bioinformatics

Biomarker discovery in urine proteome, Protein interaction and related bioinformatics.

Lori A. Henderson is a Program Director at the National Institute of Biomedical Imaging and Bioengineering (NIBIB), an institute at the National Institutes of Health (NIH), and has 17 years experience with technical and managerial expertise in several scientific areas: bioengineering, biotechnology, materials science, nanotechnology, enzymology, and biomedical technologies. She currently manages the Nanotechnology and Drug and Gene Delivery programs within the Division of Discovery Science and Technology in the Extramural Division of the NIBIB. She also represents the NIH on the National Science and Technology Council (NSTC) subcommittee on Nanoscale Science, Engineering & Technology (NSET). Her responsibilities at the NIH also include co-managing projects within the Nanomedicine, Interdisciplinary Research, and Regulatory Science programs supported by the NIH Common Fund. These trans-NIH and trans-agency programs include research projects that cut across scientific disciplines and challenges conventional thinking. Prior to the NIH, Dr. Henderson was a Group Leader of the Biomaterials Group within the Polymers Division at the National Institute of Standards and Technology (NIST). Before joining NIST in 2005, Dr. Henderson worked for Novozymes North America, BASF, and Akzo Nobel, where she was a research supervisor, global project leader, and a senior scientist. Dr. Henderson holds a M.S. degree in Macromolecular and Organic Chemistry, and obtained a Ph.D. in Polymer Science from University of Massachusetts, Lowell.

Clinical Trials Branch/Cancer Imaging Program.

David I Smith got his B.S. From the University of Wisconsin in Madison in Mathematics and Molecular Biology. He then received his Ph.D. In Biochemistry;, also from UW, Madison. After postdoctoral research at Albert Einstein College of Medicine and the University of California, Irvine, he got his first faculty position at Wayne State University. In 1996 he joined the Mayo Clinic as a full professor in the Department of Laboratory Medicine and Pathology. He is currently the Chairman of the Technology Assessment Group for the Center for Individualized Medicine at Mayo Clinic. His laboratory works on the characterization of the common fragile sites and also works to study the different roles that human papillomavirus plays in the development of cancer. His group uses the tools of next generation sequencing to address these questions.

His own research focuses on the different roles that human papillomavirus plays in the development of different cancers.

Charles J. Malemud received the Ph.D. from George Washington University in 1973 and completed postdoctoral studies at the State University of New York at Stony Brook in 1977. Since 1977, Dr. Malemud has been a member of the faculty at Case Western Reserve University School of Medicine where he is presently Professor of Medicine & Anatomy in the Division of Rheumatic Diseases and Senior Investigator in the Arthritis Research Laboratory. He has published more than 190 papers and reviews primarily in the field of chondrocyte biology. Professor Malemud is on the editorial board of several rheumatology, immunology and musculoskeletal journals and is Editor-in-Chief of the Journal of Clinical and Cellular Immunology. Close

Biology of the Musculoskeletal System, Intracellular Signal Transduction Pathways, Inflammation, Pro-inflammatory, Anti-Inflammatory &Anabolic Cytokines Apoptosis, Matrix Metalloproteinases, Osteoarthritis, Rheumatoid Arthritis, Fibromyalgia and Autoimmune Disorders

Dr. Sihem Bihorel (Ait-Oudhia) is an assistant professor at the Department of Pharmaceutics, University of Florida. Her laboratory is located at the Center for Pharmacometrics and Systems Pharmacology in Lake Nona, Orlando. In her research, Dr. Bihorel utilizes quantitative systems pharmacology approaches to guide the development of new therapies and the identification of promising combination therapies as well as of novel biomarkers in oncology. She integrates quantitative systems pharmacology with PK/PD modeling and simulation to advance drug discovery and development, and leverage the understanding of drugs action which holds great promise to facilitate translational research. Her research is also focused on investigating how priming solid tumors with pro-apoptotic agents enhances the deposition and efficacy of subsequent associated macromolecules and how these combination can be beneficial in defeating drug resistance in cancer. Prior to her current position, Dr. Bihorel was research assistant professor at the department of pharmaceutical sciences at the School of Pharmacy at the University at Buffalo (SUNY Buffalo). She also graduated with a PhD and was postdoctoral associate from the same.

Her research is also focused on investigating how priming solid tumors with pro-apoptotic agents enhances the deposition and efficacy of subsequent associated macromolecules and how these combination can be beneficial in defeating drug resistance in cancer.

Claudio Nicolini was born in Udine, Italy. He received the doctoral degree in physics from the University of Padua, in 1967. After serving as Adjunct Professor at the University of Bari, he moved for 17 years to the United States, of which he became citizen since 1974, and was originally at Brown University, MIT, and BNL. He then moved to Temple University School of Medicine, Philadelphia, where after a period of intensive training and research in pathology he became Associate Professor of Pathology and then Professor and Chairman of the Biophysics in 1976. In 1985, he was called as “eminent scientist” to the Chair of Biophysics of the University of Genoa, in Italy until 2012, where he was successively Director of Biophysics Institute, DISTBIMO and CIRSDNNOB. From 1993 until now is Life President of the Fondazione ELBA Nicolini and of the Nanoworld Institute. On 2008 has been elected as a Foreign Member of the Russian Academy of Sciences and on 2010 Honoris Causa Professor of Biophysics and Nanobiotechnology at Moscow State University. He was Chief Editor of Cell Biophysics (USA), Science and Technology Advisor to Italian Prime Minister Craxi, Member of the National Science and Technology Council upon Parliament election, Scientific Director Industrial Consortium CIREF, Founder Technobiochip; President Polo National Bioelectronics, President Scientific Technological Park of Elba Island. He received several awards and prizes and has authored more than 480 publications in international scientific journals (SCI), 35 patents (WPI), 28 books and Series Editor in Bioelectronics (Plenum) and Nanobiotechnology (Pan Stanford). His main scientific activities concerned cancer research, biophysics and nanotechnology, pioneering world-wide chromatin structure-function, bioelectronics and nanobiotechnology.

Cancer research, Biophysics and Nanotechnology, pioneering world-wide chromatin structure-function, Bioelectronics and Nanobiotechnology.

Dr. Alain Moreau is Full Professor in the Faculty of Dentistry and the Faculty of Medicine at the Universite de Montreal. He is the Director of Research and Chief Scientific Officer of Sainte-Justine University Hospital.Dr. Moreau received his PhD in Microbiology and Immunology from the Universite de Montreal in 1993. He did a first postdoctoral training at the Protein Engineering Center of University of Liege, Belgium (1992-1993), followed by a second postdoctoral fellowship at the Shriners Hospital for Children in Montreal affiliated with McGill University (1993-1997). Dr. Moreau is an internationally recognized expert on molecular genetics of pediatric scoliosis and osteoarthritis. His discoveries led to multiple peer-reviewed papers, international conferences as guest speaker, several awards as well as 32 patents issued.

Protein engineering, Molecular genetics, Biomarkers

Chee Gee See is the Director of Personalised Medicine at Proteome Sciences, a company providing high end mass-spectrometry based biomarker discovery and clinical utility tools, uniquely positioned to engage with pharma partners in our quest for personalised medicines. CheeGee was previously the clinical Biomarker and Experimental Medicine Leader at Roche for 5 years. He was the BEML for the Phase III pivotal TOGA study where Herceptin was trialled for the new indication of gastric cancer. He was also a BEML for CVD, CNS and immunology so his range and awareness of disease areas and their clinical development challenges is both deep and broad. CheeGee also spent 11 years at GSK where he was a genetics expert covering 3 key therapeutic areas in preclinical research within Genetics Research Europe. Prior to industry, CheeGee spent 6 years in post-doctoral academia at the University of Birmingham and University College London, most notably in the Human Genome Mapping Project. CheeGee also has dual specialist expertise as a consultant in regulatory affairs and value-based drug pricing, reimbursement and market access. CheeGee looks forward to engaging with like-minded professionals during this conference.

Personalised Medicine, biomarkers, genetics

Leticia Cano identified a native citrullinated autoantigen for rheumatoid arthritis for her PhD dissertation. She did her postdoctoral training in the laboratory of Hank Fales at the National Institutes of Health, where she identified candidate biomarkers for Dermatomyositis, Juvenile Idiopathic Arthritis, and Systemic Lupus Erythematosus. As founder and president of Biomarker Profiles Corporation, she is interested in developing methods to increase the speed of biomarker discovery.

Biomarkers

Pavel Vodicka graduated at the Medical Faculty, Charles University, Prague and in 1986 obtained PhD in biochemistry. He worked as postdoctoral fellow at the Finnish Inst. Occupat. Health, Helsinki, Finland (1987-1990) and as visiting scientist at Karolinska Institute, Huddinge, Sweden (1990-1993). Since 2002 he heads the Dept. Molec. Biol. Cancer, Inst. Exper. Medicine, Acad. Sci., Prague, Czech Republic. Pavel Vodicka has published more than 130 (total IF 552.4, 2650 citations a HI 31) articles. Since 2004, his main research topics are focused on the DNA and chromosomal damage and DNA repair functional tests in humans and on transient biomarkers in the onset of gastrointestinal cancers. In 2012 he edited the Special Issue in Mutagenesis http://mutage.oxfordjournals.org/content/27/2.toc), entitled Colorectal Cancer-Current Insights into Susceptibility.

Biochemistry, Molecular biology, biomarkers, cancer biology

Leticia Cano identified a native citrullinated autoantigen for rheumatoid arthritis for her Ph.D. dissertation. She did her postdoctoral training in the laboratory of Hank Fales at the National Institutes of Health, where she identified candidate biomarkers for Dermatomyositis, Juvenile Idiopathic Arthritis Systemic Lupus Erythematosis. As Founder and President of Biomarker Profiles Corporation, she is interested in developing methods to increase the speed of biomarker discovery.

she is interested in developing methods to increase the speed of biomarker discovery.

Pavel Vodicka graduated at the Medical Faculty, Charles University, Prague and in 1986 obtained Ph.D. in biochemistry. He worked as postdoctoral fellow at the Finnish Institute of Occupational Health, Helsinki, Finland (1987-1990) and as visiting scientist at Karolinska Institute, Huddinge, Sweden (1990-1993). Since 2002 he heads the Dept Molec. Biol. Cancer, Inst. Exper. Medicine, Acad. Sci., Prague, Czech Republic. He has published more than 100 (2430 citations, HI 30) articles. Since 2004, his main research topics are focused on the DNA and chromosomal damage and DNA repair functional tests in humans and on transient biomarkers in the onset of gastrointestinal cancers.

His main research topics are focused on the DNA and chromosomal damage and DNA repair functional tests in humans and on transient biomarkers in the onset of gastrointestinal cancers.

Gabriella Baio studied Medicine and Surgery at University of Pisa and she obtained Radiology specialization at University of Genoa in 2007. Since 2008, she works as Radiologist at IRCCS Azienda Ospedaliera Universitaria San Martino-IST-National Cancer Institute, in Genoa. Dott. Baio research activities, cover clinical and preclinical molecular imaging by Magnetic Resonance and Optical Imaging applied to oncology, vascular and neuroscience. Her current research consist in the characterization of breast cancer in animal model, in order to validate new contrast agents as potential biomarkers for early diagnosis and drug delivery. She is invited speaker to national and international conferences and an active member of the European Society of Molecular Imaging (ESMI). She has been Abstract Reviewer for the World Molecular Imaging Congress (WMIC) 2011 and 2012.

she works as Radiologist at IRCCS Azienda Ospedaliera Universitaria San Martino-IST-National Cancer Institute, in Genoa. Dott. Baio research activities, cover clinical and preclinical molecular imaging by Magnetic Resonance and Optical Imaging applied to oncology, vascular and neuroscience. Her current research consist in the characterization of breast cancer in animal model, in order to validate new contrast agents as potential biomarkers for early diagnosis and drug delivery. She is invited speaker to national and international conferences and an active member of the European Society of Molecular Imaging (ESMI). She has been Abstract Reviewer for the World Molecular Imaging Congress (WMIC) 2011 and 2012.

Professor Marija Krstic-Demonacos has completed her Ph.D. from University of California San Francisco, postdoctoral studies from Glasgow University and was a Lecturer and Principal Investigator in the University of Manchester. She was a recipient of a prestigious Wellcome Trust fellowship and was recently awarded the Honorary Visitor status in the University of Manchester and a Chair in Molecular Medicine in the University of Salford. She has published 43 papers in reputed journals and is serving as an editorial board member of several journals. In addition, commercialization potential of her research is evidenced by the three patents she owns. She was invited to present, chair and organize numerous conferences and has served as reviewer for various funding bodies and journals.

In particular my research group investigates effects of p53, nuclear hormone receptors and histone acetyltransferases on cell proliferation, survival, stress response, brain function and childhood cancer. Our studies aim to analyse the transcription factor activity in stem cells and leukaemia. Our target is to improve treatments and develop novel pharmacologically beneficial approaches to treat cancer.This knowledge can find application in the pharmaceutical industry and medicine.

Afaf El-Ansary, female, biochemist, graduated from biochemistry department, Ain Shams University, Egypt in 1974. She worked in the National Reserch Centre, Egypt from 1976-2000, since 2001, she is working in biochemistry department, King Saud University, KSA. She has published more than 45 papers related to metabolic integration between schistosome parasite and molluscan hosts. She recorded a patent on the “Use of sublethal concentration of solanum nigrum plant for the control of schistosomiasis". She was recognized by the Marquis Who's Who in science and engineering, Eight's edition, 2005-2006. She is member in number of national and international societies and she is recorded as reviewer in many international journals. In recent year she focused on the screening of biochemical markers related to autism and she got another 40 published papers in high impact factor Journals related to this research interest. She is member in Predictive, Preventive and Personalized Medicine Society (Moscow).

She worked in the National Reserch Centre, Egypt from 1976-2000, since 2001, she is working in biochemistry department, King Saud University, KSA. She has published more than 45 papers related to metabolic integration between schistosome parasite and molluscan hosts. She recorded a patent on the “Use of sublethal concentration of solanum nigrum plant for the control of schistosomiasis". She was recognized by the Marquis Who's Who in science and engineering, Eight's edition, 2005-2006. She is member in number of national and international societies and she is recorded as reviewer in many international journals. In recent year she focused on the screening of biochemical markers related to autism and she got another 40 published papers in high impact factor Journals related to this research interest. She is member in Predictive, Preventive and Personalized Medicine Society (Moscow).

Tao Chen has completed his Ph.D. from University of Arkansas for Medical Sciences, diplomat of the American Board of Toxicology and postdoctoral studies from Duke University. He has been a Principal Investigator in National Center for Toxicological Research since 2010 and is also an Adjunct Professor in two universities. He has served as an editorial board member and reviewer in a number of journals, a consultant for the World Health Organization, a reviewer for research proposals for US National Science Foundation. He has published more than 200 manuscripts and abstracts in peer-reviewed journals and books, and scientific meetings.

He has been a Principal Investigator in National Center for Toxicological Research

Lori A. Henderson is a Program Director at the National Institute of Biomedical Imaging and Bioengineering (NIBIB), an institute at the National Institutes of Health (NIH), and has 17 years experience with technical and managerial expertise in several scientific areas: bioengineering, biotechnology, materials science, nanotechnology, enzymology, and biomedical technologies. She currently manages the Nanotechnology and Drug and Gene Delivery programs within the Division of Discovery Science and Technology in the Extramural Division of the NIBIB. She also represents the NIH on the National Science and Technology Council (NSTC) subcommittee on Nanoscale Science, Engineering & Technology (NSET). Her responsibilities at the NIH also include co-managing projects within the Nanomedicine, Interdisciplinary Research, and Regulatory Science programs supported by the NIH Common Fund. These trans-NIH and trans-agency programs include research projects that cut across scientific disciplines and challenges conventional thinking. Prior to the NIH, Dr. Henderson was a Group Leader of the Biomaterials Group within the Polymers Division at the National Institute of Standards and Technology (NIST). Before joining NIST in 2005, Dr. Henderson worked for Novozymes North America, BASF, and Akzo Nobel, where she was a research supervisor, global project leader, and a senior scientist. Dr. Henderson holds a M.S. degree in Macromolecular and Organic Chemistry, and obtained a Ph.D. in Polymer Science from University of Massachusetts, Lowell.

Clinical Trials Branch/Cancer Imaging Program

Alan Prem Kumar earned his Ph.D. from University of North Texas, USA. From his Ph.D. work, he discovered a novel regulatory protein, PyrR for the pyrimidine biosynthetic pathway in Pseudomonas. Dr. Kumar then pursued Postdoctoral training in Cancer Research at Sidney Kimmel Cancer Center, California, USA. He was awarded a Postdoctoral Fellowship for his work on the role of nuclear receptors. Dr. Kumar relocated back to Singapore to join Cancer Science Institute of Singapore, National University of Singapore as an independent Principal Investigator to continue on his expertise on nuclear receptor and cancer pharmacology. His current research interest includes the role of nuclear receptors involved in the regulation of target genes and to elucidate mechanism and associated signal pathways. Another area of interest is aimed at developing new derivative drugs with hopefully fewer side effects. Over the years, Dr. Kumar and his laboratory have forged relationships with scientists in cancer research and with cancer advocacy groups in Singapore.

My primary research focuses in the areas of signaling by nuclear receptors and oncogenes as well as the development of molecular therapeutics and biomarkers of drug action in human breast cancer. We recently identified a novel oncogene that regulates a key pathway controlling cell proliferation, migration and drug resistance in breast, prostate, gastric, and colon cancers. Current research also focuses on developing therapeutic strategies to target this marker with the ultimate aim of conducting translational studies in patients.

Research and Working experience: March 2011-date as Assistant Research Professor, Biosample Repository Facility, Fox Chase Cancer Center, Philadelphia. Jan 2006-Dec 2010 as Instructor, Department of Pathology and Laboratory Medicine, UMDNJ-Robert Wood Johnson Medical School, New Jersey. March 2002 - Jan 2006 as Research Associate, Fox Chase Cancer Center, Philadelphia. Aug 2000 - Feb 2002 as Postdoc Associate, Fox Chase Cancer Center, Philadelphia. Apr 1997 - July 2000 Faculty member (instructor), Department of Anatomy and Cell Biology, Kagoshima University Faculty of Medicine, Japan. Aug 1990 - Jan 1993 Microbiology Inspector, Import and Export Commodities Inspection Bureau, GuangZhou, China.

Immunohistochemistry (IHC) for both basic and clinical research, Gene regulation on embryogenesis, organogenesis, tumorigenesis and multi-drug resistance, automatic quantitative analysis (AQUA) on both basic and clinical research, particularly in biomarker characterization and discovery, Ovarian cancer biology, understanding the molecular alterations of known and novel signaling pathways that regulate embryogenesis, organ morphogenesis, preneoplastic transformation and tumorigenicity

Neil Box is a Assistant Professor in the Department of Dermatology at the University of Colorado Denver. He is a member of the University of Colorado Cancer Center, Skin Diseases Research Center and the Charles C. Gates Regenerative Medicine and Stem Cell Biology Center. He is an active member of the Skin Cancer Tissue Bank executive committee. He has received Research Career Development Awards from the Dermatology Foundation and the American Skin Association. Dr. Box completed his graduate school training on the genetics of human hair, skin and eye color in the laboratory of Dr. Richard Sturm at the University of Queensland, Australia. During this period he identified some of the key red hair color variants at the MC1R locus (eg. R151C, R160W). His subsequent research on this subject produced some of the seminal melanoma association and gene interaction studies for MC1R. Since moving to the USA in 2001, he performed postdoctoral trained with two leading scientists in mouse models of human disease: Dr. Monica Justice and Dr. Dennis Roop at Baylor College of Medicine. From this work, he has assembled a research program aimed at uncovering the molecular mechanisms regulating melanoma risk. Since his recruitment to the University of Colorado in 2007, he has also continued his interests in working with human melanoma risk genes to explore their potential clinical and public health applications.

The mouse as a model for human melanocyte and melanoma development.

Yuxun Wang is currently the Executive Director and Head of Cancer Biology at HD Biosciences. He has a blend of experiences in both academia and biopharmaceutical industry in the US. Previously, he was associate director at Metamark Genetics, assistant professor at University of South Carolina and senior scientist at Merck Research Laboratory. His research has focused on translational oncology, cancer drug and predictive biomarker discovery. He has over 24 research publications and patent, numerous conference presentations and invited talks. He has received a number of awards recognizing his research and service in both academia and industry.

Head of Cancer Biology at HD Biosciences. He has a blend of experiences in both academia and biopharmaceutical industry in the US

Geetika Chakravarty's research is geared towards the identification and evaluation of new cancer stem cell biomarkers and novel strategies to target them using breast cancer as the model system. Her research has resulted in patents, invited book chapter and several first and co-authored publications. She is also dedicated to help maintain the most rigorous standards of scientific inquiry and progress and as such serves as the editorial board member and journal reviewer of cancer related journals.

Her research is geared towards the identification and evaluation of new cancer stem cell biomarkers and novel strategies to target them using breast cancer as the model system. Her research has resulted in patents,

Sevtap Savas obtained her Ph.D. in Molecular Biology and Genetics in 1999. She was trained as a post-doctoral trainee and a Research Associate at Louisiana State University (USA), Mount Sinai Hospital Research Institute (Canada) and Princess Margaret Hospital/Ontario Cancer Institute (Canada), before joining the Memorial University (Canada) as an Assistant Professor in 2008. She has a multidisciplinary research program integrating molecular genetics, bioinformatics, biostatistics and epidemiology and currently focuses on identification of genetic markers that can predict clinical outcome in colorectal cancer patients.

Role of genetic variation in cancer susceptibility; Role of genetic variation in treatment response (pharmacogenetic), Role of genetic variation in clinical outcomes and survivorship in cancer; Role of somatic mutations in cancer predisposition treatment response and clinical outcome; Role of mitochondrial genome in cancer predisposition, treatment response and clinical outcome; Bioinformatics application and establishment of biological databases, High-throughput genotyping technologies and resequencing studies

Yaguang Xi got the Ph.D from Peking University after his clinical training. He is an Assistant Professor at the University of South Alabama Mitchell Cancer Institute. To date, Dr. Xi has authored 43 publications in many prestigious journals and is serving as the member of editorial board and ad-hoc reviewer for many journals and grant agencies.

Discovery and validation of novel biomarkers associated with tumor progression, metastasis, therapeutic response and chemoprevention,

Michael Holinstat is an assistant professor of Medicine at Thomas Jefferson University in Philadelphia. He received his Ph.D. in Pharmacology from the University of Illinois at Chicago and postdoctoral training at Vanderbilt University in the Department of Pharmacology. His research focuses on identifying novel approaches to anti-platelet therapy with a special emphasis on regulation of platelets through the lipoxygenase pathway leading to a number of oxidized fatty acids which may play a central role in regulating unwanted platelet activation. Additionally, the lab studies regulation of platelet signaling through PAR1 and PAR4.

Thrombosis; Rap1; Gpcr; Signal Transduction; Platelet; Pharmacology; Hematology; Medicine; Small G Protein; Signal Transduction; Signaling; Lipoxygenase; 12-Lipoxygenase; 12-HETE; 12-HETrE.

Feng Yan, has completed her Ph.D from Yangzhou University in China. She is the Vice Director of Department of Clinical Laboratory in Jiangsu Cancer Hospital, and an Professor of Nanjing Medical University. The research works of Feng Yan focus on the bioanalytical chemistry in laboratory medical diagnostics, particularly in detection of tumor markers and tumor cells. She was the Outstanding Medical Talents (2007), Excellent Medical Talent (2011) and Leading Medical Talent (2011) of Jiangsu Province. She has published more than 42 papers in reputed journals.

The research works of Feng Yan focus on the bioanalytical chemistry in laboratory medical diagnostics, particularly in detection of tumor markers and tumor cells.

Jamal Zweit is a Professor of Radiology, Radiation Oncology, Molecular Pathology, and Biochemistry & Molecular Biology. He is also the Director of the Center for Molecular Imaging at Virginia Commonwealth University Medical Center. He leads an inter-disciplinary and inter-collaborative molecular imaging research program that emphasizes multi-modality approaches to study biochemical and biological pathways in vivo. Professor Zweit's research interests include the development of paradigms for molecular imaging and nanotechnology strategies for preclinical and clinical translational research in cancer biology and therapeutics. He is internationally recognized for his work in molecular imaging of cancer drug development, and conducted the "world’s first" Molecular PET Imaging clinical trial of Anti-angiogenic therapy in cancer patients (Journal National Cancer Institute 2002). Professor Zweit serves as an advisor on a number of committees, including the Cancer Research UK Pharmacodynamic and Pharmacokiunetic Technologies Advisory Committee (Journal National Cancer Institute, 2006). He serves on the review body of a number of funding organizations, both in Europe and North America. He has supervised a total of 24 MSc, MD and PhD theses. He has published more than 100 peer reviewed articles, over 250 conference abstracts, and 6 review articles and book chapters. Professor Zweit obtained his PhD and DSc from the University of Manchester Medical School. Prior to that, He studied for an MSc degree in PET Pharmacology. He received his Nuclear Medicine training at the John F. Kennedy Medical Centre in New Jersey, and attended advanced Nuclear Medicine training at the Brooklyn Hospital in New York As an Undergraduate, he obtained his Bachelor of Science degree, in Radiation Biophysics, with a Biochemistry double major, from the University of Kansas.

Multi-modality molecular and cellular imaging. Biologically targeted probe development and ulti-probe pre-clinical imaging. Nano-particle and quantum dot molecular and cellular imaging. Translational clinical molecular imaging in drug development. Pharmacokinetics and pharmacodynamics studies in oncology and neuroscience.

Dr. Bowser is Chairman of Neurobiology and Director of the Gregory W. Fulton ALS and Neuromuscular Research Center at the Barrow Neurological Institute and St. Joseph's Hospital and Medical Center in Phoenix, AZ. He obtained his PhD from Yale University School of Medicine and was a faculty member at the University of Pittsburgh School of Medicine for 18 years prior to his arrival in Phoenix in 2011. Dr. Bowser is also co-Founder of Knopp Biosciences, LLC and Iron Horse Diagnostics, Inc., biotechnology companies advancing new treatments and ways to diagnose neurologic disorders. Iron Horse Diagnostics is commercializing the first diagnostic test for ALS. Dr. Bowser's research interests are to determine the molecular and cellular basis of motor neuron cell death in ALS and translate these findings to the clinic. His laboratory leads efforts in the discovery and validation of protein biomarkers for ALS. Dr. Bowser also pursues methods to monitor ALS disease progression and drug effects during clinical trials. He has national and international leadership positions in the field of ALS, and co-Chairs a national ALS Biorepository, providing biofluid and tissue samples collected using standardized procedures to ALS investigators throughout the country.

Dr. Bowser's research interests are to determine the molecular and cellular basis of motor neuron cell death in ALS and translate these findings to the clinic. His laboratory leads efforts in the discovery and validation of protein biomarkers for ALS. Dr. Bowser also pursues methods to monitor ALS disease progression and drug effects during clinical trials. He has national and international leadership positions in the field of ALS, and co-Chairs a national ALS Biorepository, providing biofluid and tissue samples collected using standardized procedures to ALS investigators throughout the country.

Jagat Kanwar is an Immunologist and Molecular Biochemist. He is group leader of the Laboratory of Immunology and Molecular Biomedical Research. Kanwar's research work generated in total of 12 patent/PCTs with two provisionals in preparation. Five of these patents have been licensed for commercialization to biotech companies Antisoma, NeuronZ, Neuren Pharmaceuticals and Fonterra. He was invited as a speaker in more than 30 conferences and chaired sessions in Immunology, Nanotechnology, Nanomedicine and Biotechnology.

Nanomedicine, multi-targeted oral or intravenous delivery systems, nano-medicinal based vaccines and immunotherapy, micro-fluidics and lab-on-a-chip devices.

Assistant Professor & Director MEBRL, Division of Epidemiology, 1990-Present, School of Public Health, University of Minnesota Minneapolis, MN Research Associate, Division of Epidemiology, 1987-1990, School of Public Health, University of Minnesota, Minneapolis, MN Research Fellowship, National Research Service Award, 1984-1987 Endocrine Research Unit, Mayo Clinic, Rochester, MN Dr. Gross is Director of the Molecular Epidemiology and Biomarker Research Laboratory at the University of Minnesota. He has overseen analysis for numerous epidemiologic projects and has published extensively in the areas of antioxidants and oxidative damage. His experience includes serving as principal investigator of the laboratory core for the University of Minnesota CPRU program project, co-principal investigator of YALTA and as co-investigator of several clinical trials and epidemiologic studies emphasizing diet, genetics and biological markers. His laboratory has served as an analytical facility for several multicenter studies including CARDIA, ARIC and CATCH. Sample tracking, data handling, biochemical analysis and sample storage for large epidemiologic studies are a routine part of his laboratory.

Biomarker development/translational research, molecular/biochemical epidemiology, antioxidants, oxidative damage and risk of cardiovascular disease, DNA repair and genetic susceptibility in the risk of breast cancer, early detection of pancreatic prostate cancer, dietary and genetic factors in Alzheimer’s and successful aging

Tao Chen has completed his Ph.D. from University of Arkansas for Medical Sciences, diplomat of the American Board of Toxicology and postdoctoral studies from Duke University. He has been a Principal Investigator in National Center for Toxicological Research since 2010 and is also an Adjunct Professor in two universities. He has served as an editorial board member and reviewer in a number of journals, a consultant for the World Health Organization, a reviewer for research proposals for US National Science Foundation. He has published more than 200 manuscripts and abstracts in peer-reviewed journals and books, and scientific meetings.

He has been a Principal Investigator in National Center for Toxicological Research

Lori A. Henderson is a Program Director at the National Institute of Biomedical Imaging and Bioengineering (NIBIB), an institute at the National Institutes of Health (NIH), and has 17 years experience with technical and managerial expertise in several scientific areas: bioengineering, biotechnology, materials science, nanotechnology, enzymology, and biomedical technologies. She currently manages the Nanotechnology and Drug and Gene Delivery programs within the Division of Discovery Science and Technology in the Extramural Division of the NIBIB. She also represents the NIH on the National Science and Technology Council (NSTC) subcommittee on Nanoscale Science, Engineering & Technology (NSET). Her responsibilities at the NIH also include co-managing projects within the Nanomedicine, Interdisciplinary Research, and Regulatory Science programs supported by the NIH Common Fund. These trans-NIH and trans-agency programs include research projects that cut across scientific disciplines and challenges conventional thinking. Prior to the NIH, Dr. Henderson was a Group Leader of the Biomaterials Group within the Polymers Division at the National Institute of Standards and Technology (NIST). Before joining NIST in 2005, Dr. Henderson worked for Novozymes North America, BASF, and Akzo Nobel, where she was a research supervisor, global project leader, and a senior scientist. Dr. Henderson holds a M.S. degree in Macromolecular and Organic Chemistry, and obtained a Ph.D. in Polymer Science from University of Massachusetts, Lowell.

Clinical Trials Branch/Cancer Imaging Program

Alan Prem Kumar earned his Ph.D. from University of North Texas, USA. From his Ph.D. work, he discovered a novel regulatory protein, PyrR for the pyrimidine biosynthetic pathway in Pseudomonas. Dr. Kumar then pursued Postdoctoral training in Cancer Research at Sidney Kimmel Cancer Center, California, USA. He was awarded a Postdoctoral Fellowship for his work on the role of nuclear receptors. Dr. Kumar relocated back to Singapore to join Cancer Science Institute of Singapore, National University of Singapore as an independent Principal Investigator to continue on his expertise on nuclear receptor and cancer pharmacology. His current research interest includes the role of nuclear receptors involved in the regulation of target genes and to elucidate mechanism and associated signal pathways. Another area of interest is aimed at developing new derivative drugs with hopefully fewer side effects. Over the years, Dr. Kumar and his laboratory have forged relationships with scientists in cancer research and with cancer advocacy groups in Singapore.

My primary research focuses in the areas of signaling by nuclear receptors and oncogenes as well as the development of molecular therapeutics and biomarkers of drug action in human breast cancer. We recently identified a novel oncogene that regulates a key pathway controlling cell proliferation, migration and drug resistance in breast, prostate, gastric, and colon cancers. Current research also focuses on developing therapeutic strategies to target this marker with the ultimate aim of conducting translational studies in patients.

Research and Working experience: March 2011-date as Assistant Research Professor, Biosample Repository Facility, Fox Chase Cancer Center, Philadelphia. Jan 2006-Dec 2010 as Instructor, Department of Pathology and Laboratory Medicine, UMDNJ-Robert Wood Johnson Medical School, New Jersey. March 2002 - Jan 2006 as Research Associate, Fox Chase Cancer Center, Philadelphia. Aug 2000 - Feb 2002 as Postdoc Associate, Fox Chase Cancer Center, Philadelphia. Apr 1997 - July 2000 Faculty member (instructor), Department of Anatomy and Cell Biology, Kagoshima University Faculty of Medicine, Japan. Aug 1990 - Jan 1993 Microbiology Inspector, Import and Export Commodities Inspection Bureau, GuangZhou, China.

Immunohistochemistry (IHC) for both basic and clinical research, Gene regulation on embryogenesis, organogenesis, tumorigenesis and multi-drug resistance, automatic quantitative analysis (AQUA) on both basic and clinical research, particularly in biomarker characterization and discovery, Ovarian cancer biology, understanding the molecular alterations of known and novel signaling pathways that regulate embryogenesis, organ morphogenesis, preneoplastic transformation and tumorigenicity

Neil Box is a Assistant Professor in the Department of Dermatology at the University of Colorado Denver. He is a member of the University of Colorado Cancer Center, Skin Diseases Research Center and the Charles C. Gates Regenerative Medicine and Stem Cell Biology Center. He is an active member of the Skin Cancer Tissue Bank executive committee. He has received Research Career Development Awards from the Dermatology Foundation and the American Skin Association. Dr. Box completed his graduate school training on the genetics of human hair, skin and eye color in the laboratory of Dr. Richard Sturm at the University of Queensland, Australia. During this period he identified some of the key red hair color variants at the MC1R locus (eg. R151C, R160W). His subsequent research on this subject produced some of the seminal melanoma association and gene interaction studies for MC1R. Since moving to the USA in 2001, he performed postdoctoral trained with two leading scientists in mouse models of human disease: Dr. Monica Justice and Dr. Dennis Roop at Baylor College of Medicine. From this work, he has assembled a research program aimed at uncovering the molecular mechanisms regulating melanoma risk. Since his recruitment to the University of Colorado in 2007, he has also continued his interests in working with human melanoma risk genes to explore their potential clinical and public health applications.

The mouse as a model for human melanocyte and melanoma development.

Yuxun Wang is currently the Executive Director and Head of Cancer Biology at HD Biosciences. He has a blend of experiences in both academia and biopharmaceutical industry in the US. Previously, he was associate director at Metamark Genetics, assistant professor at University of South Carolina and senior scientist at Merck Research Laboratory. His research has focused on translational oncology, cancer drug and predictive biomarker discovery. He has over 24 research publications and patent, numerous conference presentations and invited talks. He has received a number of awards recognizing his research and service in both academia and industry.

Head of Cancer Biology at HD Biosciences. He has a blend of experiences in both academia and biopharmaceutical industry in the US

Geetika Chakravarty's research is geared towards the identification and evaluation of new cancer stem cell biomarkers and novel strategies to target them using breast cancer as the model system. Her research has resulted in patents, invited book chapter and several first and co-authored publications. She is also dedicated to help maintain the most rigorous standards of scientific inquiry and progress and as such serves as the editorial board member and journal reviewer of cancer related journals.

Her research is geared towards the identification and evaluation of new cancer stem cell biomarkers and novel strategies to target them using breast cancer as the model system. Her research has resulted in patents,

Sevtap Savas obtained her Ph.D. in Molecular Biology and Genetics in 1999. She was trained as a post-doctoral trainee and a Research Associate at Louisiana State University (USA), Mount Sinai Hospital Research Institute (Canada) and Princess Margaret Hospital/Ontario Cancer Institute (Canada), before joining the Memorial University (Canada) as an Assistant Professor in 2008. She has a multidisciplinary research program integrating molecular genetics, bioinformatics, biostatistics and epidemiology and currently focuses on identification of genetic markers that can predict clinical outcome in colorectal cancer patients.

Role of genetic variation in cancer susceptibility; Role of genetic variation in treatment response (pharmacogenetic), Role of genetic variation in clinical outcomes and survivorship in cancer; Role of somatic mutations in cancer predisposition treatment response and clinical outcome; Role of mitochondrial genome in cancer predisposition, treatment response and clinical outcome; Bioinformatics application and establishment of biological databases, High-throughput genotyping technologies and resequencing studies

Yaguang Xi got the Ph.D from Peking University after his clinical training. He is an Assistant Professor at the University of South Alabama Mitchell Cancer Institute. To date, Dr. Xi has authored 43 publications in many prestigious journals and is serving as the member of editorial board and ad-hoc reviewer for many journals and grant agencies.

Discovery and validation of novel biomarkers associated with tumor progression, metastasis, therapeutic response and chemoprevention,

Michael Holinstat is an assistant professor of Medicine at Thomas Jefferson University in Philadelphia. He received his Ph.D. in Pharmacology from the University of Illinois at Chicago and postdoctoral training at Vanderbilt University in the Department of Pharmacology. His research focuses on identifying novel approaches to anti-platelet therapy with a special emphasis on regulation of platelets through the lipoxygenase pathway leading to a number of oxidized fatty acids which may play a central role in regulating unwanted platelet activation. Additionally, the lab studies regulation of platelet signaling through PAR1 and PAR4.

Thrombosis; Rap1; Gpcr; Signal Transduction; Platelet; Pharmacology; Hematology; Medicine; Small G Protein; Signal Transduction; Signaling; Lipoxygenase; 12-Lipoxygenase; 12-HETE; 12-HETrE.

Feng Yan, has completed her Ph.D from Yangzhou University in China. She is the Vice Director of Department of Clinical Laboratory in Jiangsu Cancer Hospital, and an Professor of Nanjing Medical University. The research works of Feng Yan focus on the bioanalytical chemistry in laboratory medical diagnostics, particularly in detection of tumor markers and tumor cells. She was the Outstanding Medical Talents (2007), Excellent Medical Talent (2011) and Leading Medical Talent (2011) of Jiangsu Province. She has published more than 42 papers in reputed journals.

The research works of Feng Yan focus on the bioanalytical chemistry in laboratory medical diagnostics, particularly in detection of tumor markers and tumor cells.

Jamal Zweit is a Professor of Radiology, Radiation Oncology, Molecular Pathology, and Biochemistry & Molecular Biology. He is also the Director of the Center for Molecular Imaging at Virginia Commonwealth University Medical Center. He leads an inter-disciplinary and inter-collaborative molecular imaging research program that emphasizes multi-modality approaches to study biochemical and biological pathways in vivo. Professor Zweit's research interests include the development of paradigms for molecular imaging and nanotechnology strategies for preclinical and clinical translational research in cancer biology and therapeutics. He is internationally recognized for his work in molecular imaging of cancer drug development, and conducted the "world’s first" Molecular PET Imaging clinical trial of Anti-angiogenic therapy in cancer patients (Journal National Cancer Institute 2002). Professor Zweit serves as an advisor on a number of committees, including the Cancer Research UK Pharmacodynamic and Pharmacokiunetic Technologies Advisory Committee (Journal National Cancer Institute, 2006). He serves on the review body of a number of funding organizations, both in Europe and North America. He has supervised a total of 24 MSc, MD and PhD theses. He has published more than 100 peer reviewed articles, over 250 conference abstracts, and 6 review articles and book chapters. Professor Zweit obtained his PhD and DSc from the University of Manchester Medical School. Prior to that, He studied for an MSc degree in PET Pharmacology. He received his Nuclear Medicine training at the John F. Kennedy Medical Centre in New Jersey, and attended advanced Nuclear Medicine training at the Brooklyn Hospital in New York As an Undergraduate, he obtained his Bachelor of Science degree, in Radiation Biophysics, with a Biochemistry double major, from the University of Kansas.

Multi-modality molecular and cellular imaging. Biologically targeted probe development and ulti-probe pre-clinical imaging. Nano-particle and quantum dot molecular and cellular imaging. Translational clinical molecular imaging in drug development. Pharmacokinetics and pharmacodynamics studies in oncology and neuroscience.

Dr. Bowser is Chairman of Neurobiology and Director of the Gregory W. Fulton ALS and Neuromuscular Research Center at the Barrow Neurological Institute and St. Joseph's Hospital and Medical Center in Phoenix, AZ. He obtained his PhD from Yale University School of Medicine and was a faculty member at the University of Pittsburgh School of Medicine for 18 years prior to his arrival in Phoenix in 2011. Dr. Bowser is also co-Founder of Knopp Biosciences, LLC and Iron Horse Diagnostics, Inc., biotechnology companies advancing new treatments and ways to diagnose neurologic disorders. Iron Horse Diagnostics is commercializing the first diagnostic test for ALS. Dr. Bowser's research interests are to determine the molecular and cellular basis of motor neuron cell death in ALS and translate these findings to the clinic. His laboratory leads efforts in the discovery and validation of protein biomarkers for ALS. Dr. Bowser also pursues methods to monitor ALS disease progression and drug effects during clinical trials. He has national and international leadership positions in the field of ALS, and co-Chairs a national ALS Biorepository, providing biofluid and tissue samples collected using standardized procedures to ALS investigators throughout the country.

Dr. Bowser's research interests are to determine the molecular and cellular basis of motor neuron cell death in ALS and translate these findings to the clinic. His laboratory leads efforts in the discovery and validation of protein biomarkers for ALS. Dr. Bowser also pursues methods to monitor ALS disease progression and drug effects during clinical trials. He has national and international leadership positions in the field of ALS, and co-Chairs a national ALS Biorepository, providing biofluid and tissue samples collected using standardized procedures to ALS investigators throughout the country.

Jagat Kanwar is an Immunologist and Molecular Biochemist. He is group leader of the Laboratory of Immunology and Molecular Biomedical Research. Kanwar's research work generated in total of 12 patent/PCTs with two provisionals in preparation. Five of these patents have been licensed for commercialization to biotech companies Antisoma, NeuronZ, Neuren Pharmaceuticals and Fonterra. He was invited as a speaker in more than 30 conferences and chaired sessions in Immunology, Nanotechnology, Nanomedicine and Biotechnology.

Nanomedicine, multi-targeted oral or intravenous delivery systems, nano-medicinal based vaccines and immunotherapy, micro-fluidics and lab-on-a-chip devices.

Assistant Professor & Director MEBRL, Division of Epidemiology, 1990-Present, School of Public Health, University of Minnesota Minneapolis, MN Research Associate, Division of Epidemiology, 1987-1990, School of Public Health, University of Minnesota, Minneapolis, MN Research Fellowship, National Research Service Award, 1984-1987 Endocrine Research Unit, Mayo Clinic, Rochester, MN Dr. Gross is Director of the Molecular Epidemiology and Biomarker Research Laboratory at the University of Minnesota. He has overseen analysis for numerous epidemiologic projects and has published extensively in the areas of antioxidants and oxidative damage. His experience includes serving as principal investigator of the laboratory core for the University of Minnesota CPRU program project, co-principal investigator of YALTA and as co-investigator of several clinical trials and epidemiologic studies emphasizing diet, genetics and biological markers. His laboratory has served as an analytical facility for several multicenter studies including CARDIA, ARIC and CATCH. Sample tracking, data handling, biochemical analysis and sample storage for large epidemiologic studies are a routine part of his laboratory.

Biomarker development/translational research, molecular/biochemical epidemiology, antioxidants, oxidative damage and risk of cardiovascular disease, DNA repair and genetic susceptibility in the risk of breast cancer, early detection of pancreatic prostate cancer, dietary and genetic factors in Alzheimer’s and successful aging